FDA warns Alere for cardiac DX quality shortfalls

The FDA is taking Alere ($ALR) to task for not acting fast enough to address manufacturing problems with its Triage cardiac diagnostic products. An Oct. 22 warning letter issued to the Waltham, MA, company cites the company for quality system violations involving its manufacturing specifications, and how the company verifies those processes worked properly. Also, regulators said, Alere hasn't adequately addressed more than three dozen complaints regarding code chips used for its tests that didn't function as intended. Warning letter

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.